Scholars Central

Conference abstractPublished 27 Dec 2017

Modulating microbiota for IBD control

Authors: Yunsheng Yang, Rongrong Ren, Yichao Shi, Zhengpeng Li, Jing Chen, Jianfeng Li, Gang Sun, Lihua Peng

Chinese PLA General Hospital, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Prevalence of IBD in Asia is still lower than that in western countries, however it is increasing in recent years. The pathogenesis of IBD remains unclear and more evidences reveal intestinal microbiota to play an important role in IBD, especially in ulcerative colitis UC. Therapies via modulating gut microbiota have been introduced to IBD, including probiotics, prebiotics and fecal microbiota transplantation (FMT). Gut microbiota reconstruction has been becoming a trending topic in IBD, clinical medicine and life science. The lecture will report our FMT trial to treat IBD and other relevant studies. Prebiotics and Probiotics to treat IBD: In clinical investigations, prebiotics such as oligofructose and probiotics such as VSL#3, EcN have been observed to treat active UC patients, which showed some of such preparations were able to relieve IBD. Fecal Microbiota Transplantation to treat IBD: We reviewed FMT treatment for IBD and report our clinical trial with FMT for treating the IBD. In a pilot study for UC patients, the clinical manifestations and laboratory results improved significantly with an apparent reduction of Mayo Scores and Endoscopic Mayo Scores in seven months follow-up. In a consequent cohort study, patients with severe or refractory UC received FMT. Significant reduction of Mayo Scores and Endoscopic Mayo Scores were obtained after FMT. The clinical remission rate was from 47.1% to 64.7%, and the endoscopic remission rate was from 52.9% to 76.5%. Only a few adverse reactions were observed, such as abdominal discomfort and low fever emerged transiently. Microbiome sequencing showed that the diversity of intestinal microbiota of UC patients was reconstructed and transformed to healthy donorâÂ?Â?s gradually after FMT. Finally, the lecture makes a prospective of IBD treatment through the modulation of gut microbiota with synthetic microbes under development. Conclusion: Microbiota modulation is a promising and effective modality for IBD especially ulcerative colitis. Further studies regarding the clinical RCT, multi-omics and molecular pathways are needed and will help us to precisely understand and use microbiota to IBD.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Gastrointestinal & Digestive System.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Gastrointestinal & Digestive System
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Yunsheng Yang”
  • BylineArticles whose byline prints “Rongrong Ren”
  • BylineArticles whose byline prints “Yichao Shi”
  • BylineArticles whose byline prints “Zhengpeng Li”
  • BylineArticles whose byline prints “Jing Chen”
  • BylineArticles whose byline prints “Jianfeng Li”
  • BylineArticles whose byline prints “Gang Sun”
  • BylineArticles whose byline prints “Lihua Peng”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels